NCCN melanoma guidelines revised to reflect emerging data for novel agents, treatment regimens

Access to the full content of this site is available only to registered healthcare professionals. Register to read more
First-line systemic therapy
  • For unresectable or metastatic disease, recommended treatment options include checkpoint immunotherapy, BRAF-targeted therapy for patients with BRAF-mutated disease, or clinical trial.
  • Checkpoint immunotherapy options include anti-programmed cell death protein-1 (PD-1)...